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This study evaluated the in vitro and in vivo pharmacological properties of TD-8954, a
potent and selective 5-HT4 receptor agonist.TD-8954 had high afﬁnity (pKi = 9.4) for human
recombinant 5-HT4(c) (h5-HT4(c)) receptors, and selectivity (>2,000-fold) over all other 5-
hydroxytryptamine (5-HT) receptors and non-5-HT receptors, ion channels, enzymes and
transporters tested (n= 78). TD-8954 produced an elevation of cAMP in HEK-293 cells
expressing the h5-HT4(c) receptor (pEC50 = 9.3), and contracted the guinea pig colonic
longitudinal muscle/myenteric plexus preparation (pEC50 = 8.6). TD-8954 had moderate
intrinsic activity in the in vitro assays. In conscious guinea pigs, subcutaneous administra-
tion of TD-8954 (0.03–3mg/kg) increased the colonic transit of carmine red dye, reducing
the time taken for its excretion. Following intraduodenal dosing to anesthetized rats, TD-
8954 (0.03–10mg/kg) evoked a dose-dependent relaxation of the esophagus. Following
oral administration to conscious dogs, TD-8954 (10 and 30μg/kg) produced an increase in
contractility of the antrum, duodenum, and jejunum. In a single ascending oral dose study in
healthy human subjects, TD-8954 (0.1–20mg) increased bowel movement frequency and
reduced the time to ﬁrst stool. It is concluded thatTD-8954 is a potent and selective 5-HT4
receptor agonist in vitro, with robust in vivo stimulatory activity in the gastrointestinal (GI)
tract of guinea pigs, rats, dogs, and humans. TD-8954 may have clinical utility in patients
with disorders of reduced GI motility.
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INTRODUCTION
5-Hydroxytryptamine (5-HT) plays a critical role in coordinating
gastrointestinal (GI) transit (Hansen and Skadhauge, 1997; Grider
et al., 1998; Jin et al., 1999; Baker, 2005). In response to intesti-
nal stretching and mucosal stimulation, 5-HT is released from
enterochromafﬁn cells of the mucosal epithelium, and promotes
peristalsis via activation of intrinsic primary afferent neurons
located in the submucous plexus (Kirchgessner et al., 1992; Foxx-
Orenstein et al., 1995; Gershon and Tack, 2007). Of the 5-HT
receptors believed to inﬂuence GI motility (e.g., 5-HT1A, 5-HT2A,
5-HT2B, 5-HT3, and 5-HT4; Beattie and Smith, 2008), the 5-
HT4 receptor subtype is considered particularly important, both
physiologically and pathophysiologically (Kadowaki et al., 1996;
Kim and Camilleri, 2000; Baker, 2005). The peristaltic reﬂex, for
example, is dependent on activation of 5-HT4 receptors on intrin-
sic primary afferent neurons, interneurons, and motor neurons
within the gut wall, which results in the coordinated release of
acetylcholine, substance P, and calcitonin gene-related peptide.
The release of these agents is associated with synchronized con-
traction and relaxation of GI smooth muscle, and propulsion
of luminal contents (Jin et al., 1999; Gershon and Tack, 2007).
Additionally, activation of 5-HT4 receptors in the smooth muscle
of the human distal colon, and on enteric neurons or enterocytes
promotes a direct relaxant effect and ﬂuid secretion, respectively,
further supporting GI transit (Hillier et al., 1994; Hansen and
Skadhauge, 1997).
Agents interacting with 5-HT3 and 5-HT4 receptors have pro-
vided meaningful beneﬁt to patients with GI functional disorders
(Sanger, 2008). The GI prokinetic activity of 5-HT4 receptor
agonists, such as tegaserod (Zelnorm®), cisapride (Propulsid®),
velusetrag (TD-5108), prucalopride (Resolor®), and mosapride
has been demonstrated in a variety of species (Jin et al., 1999;
Briejer et al., 2001b; Inui et al., 2002; Ji et al., 2003; Manini
et al., 2009), and clinical efﬁcacy has been established in patients
with irritable bowel syndrome with constipation (IBS-C), chronic
idiopathic constipation, functional dyspepsia, or gastroparesis
(Deruyttere et al., 1987; Muller-Lissner, 1987; Abell et al., 1991;
Camilleri, 2001; Johanson, 2004; Patel et al., 2004; Camilleri et al.,
2008; Goldberg et al., 2010). Cisapride and tegaserod were used
widely to treat upper and lower GI disorders of reduced motility,
respectively, although their clinical efﬁcacy in many patients was
modest (Kellow et al., 1995; Evans et al., 2004), possibly reﬂecting
their interactions with receptors other than the 5-HT4 subtype
(Briejer et al., 1995; Beattie et al., 2004; Beattie and Smith, 2008;
De Maeyer et al., 2008). The clinical use of cisapride and tegaserod
is now restricted on the basis of cardiovascular safety concerns
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(Barbey et al., 2002; Pasricha, 2007). Cisapride was associated
with serious cardiac arrhythmias including ventricular tachycar-
dia, ventricular ﬁbrillation, and torsades de pointes as a result of its
potent cardiac human ether-à-go-go-related gene (hERG) potas-
sium channel inhibitory activity (Mohammad et al., 1997). The
marketing of tegaserod was suspended in the United States due
to concerns of an increased risk of serious ischemic cardiovascu-
lar events, although two recent epidemiological studies failed to
identify such an association (Anderson et al., 2009; Loughlin et al.,
2010). The newer generation, highly selective 5-HT4 receptor ago-
nists, velusetrag and prucalopride, produce robust clinical efﬁcacy
in chronic idiopathic constipation patients, have been well tol-
erated to date, and offer renewed hope for patients experiencing
disorders of reduced GI motility (Camilleri et al., 2008; Sanger,
2009; Goldberg et al., 2010; Manabe et al., 2010). Prucalopride
is approved in Europe for the treatment of women with chronic
idiopathic constipation who have not responded adequately to
laxatives.
In this study, the in vitro and in vivo pharmaco-
dynamic properties of a structurally novel 5-HT4 recep-
tor agonist, TD-8954 (4-{(4-[(2-isopropyl-1H -benzoimidazole-
4-carbonyl)amino]methyl}- piperidin-1-ylmethyl)piperidine-1-
carboxylic acid methyl ester; Figure 1), have been investigated.
The preclinical activity of several standard 5-HT4 agonists was
evaluated in parallel for comparison to that of TD-8954.
MATERIALS AND METHODS
All animal experiments were conducted in accordance with the
principles of good laboratory animal care provided by the Insti-
tutional Animal Care and Use Committees of Theravance, Inc.
(rodent studies) or Drug Research Laboratories (dog study). The
study protocol and consent form for the human single ascending
dose study were reviewed by the clinical site’s Institutional Review
Board, and each volunteer provided written informed consent
prior to initiation of study procedures. The study was conducted
at a single site in accordancewith theUnited States Code of Federal
Regulations and the principles of the Declaration of Helsinki.
HUMAN RECOMBINANT 5-HT4 RECEPTORS
Radioligand binding
Radioligand binding studies were conducted as described previ-
ously (Smith et al., 2008). Inhibition of [3H]-GR113808 bind-
ing was measured using membranes prepared from HEK293
cells stably expressing the human 5-HT4(c) (h5-HT4(c)) receptor
splice variant (HEK293-h5-HT4(c)) (Kaumann and Levy, 2006).
FIGURE 1 |TD-8954 (4-(4-{[(2-isopropyl-1H -benzoimidazole-4-
carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic
acid methyl ester).
5-HT4(c) receptor mRNA was been detected in human GI tissue
by RT-PCR (Blondel et al., 1998; Bender et al., 2000; Medhurst
et al., 2001; Ito et al., 2003), and the rank order of afﬁnities or
potencies for several agonist and antagonists is maintained across
5-HT4 receptor splice variants in published reports (Blondel et al.,
1998; Smith et al., 2008), supporting the use of the 5-HT4(c) variant
for the current studies. Unlabeled compound (10 pM to 100μM)
was incubated for 1 h at room temperature with [3H]-GR113808
(0.15 nM) and h5-HT4(c) membranes (2μg protein) in a total
assay volume of 400μL. Binding reactions were terminated by
rapid ﬁltration over GF/B ﬁlter plates and bound radioactivity
quantitated by liquid scintillation spectroscopy in Microscint-
20 using a TopCount Scintillation Counter (Packard BioScience,
Meriden, CT, USA).
Binding data were analyzed by non-linear regression analy-
sis using GraphPad Prism™ software (GraphPad Software, Inc.,
San Diego, CA, USA) and a three-parameter model for one-site
competition. The pKi (negative decadic logarithm of Ki) values
for test compounds were calculated from the best-ﬁt IC50 values,
and the Kd value of the radioligand, using the Cheng–Prusoff
equation [Cheng and Prusoff, 1973; Ki = IC50/(1+ [L]/Kd)
where [L]= radioligand concentration], and are reported as the
mean± SEM. Standard compounds were evaluated in parallel
with TD-8954; the pKi values were consistent with those reported
previously (Vickery et al., 2007; Smith et al., 2008).
Whole cell cAMP accumulation
Whole cell cAMP accumulation assays were performed as
described previously (Smith et al., 2008) using a homogeneous
radioimmunoassay (Flashplate Adenylyl Cyclase Activation Assay
System; Perkin Elmer Life Sciences, Boston, MA, USA). HEK293-
h5-HT4(c) cells were lifted in Versene and collected by centrifu-
gation (1,200× g, 5min) in phosphate-buffered saline (PBS). The
cell pellet was resuspended gently in warm “stimulation buffer”
(provided in the assay kit) and diluted to 5× 105 cells/mL. Cells
(25,000 per well) were incubated with test compound (10 pM to
100μM) for 15min at 37˚C in a 96-well Flashplate, in a total
volume of 0.1mL. In antagonist inhibition studies, cells were
preincubated in the absence or presence of GR113808 (0.6, 1.7,
or 5 nM) for 20min at 37˚C prior to the addition of the test
agonist. After the incubation period, [125I]-cAMP was added in
100˚μL of ice-cold “detection buffer” to each well, according to
the manufacturer’s instructions. Bound radioactivity was quanti-
ﬁed by scintillation counting and the amount of cAMP produced
was extrapolated from a cAMP standard curve.
Data were analyzed by non-linear regression analysis
with GraphPad Prism™ using the three-parameter sigmoidal
concentration–effect model (slope constrained to unity). The
potency of test agents was reported as a mean (±SEM) pEC50
value (negative decadic logarithm of the effective concentration
producing 50% of the maximum response), and the intrinsic
activity (IA) as a mean (±SEM) percentage of the maximum
5-HT-evoked response. The pEC50 and IA values for standard
compounds (tested in parallel with TD-8954) were consistent with
those reported previously (Vickery et al., 2007; Smith et al., 2008).
Schild regression analysis was used to determine pKb values for
GR113808 in the antagonist inhibition studies for 5-HT and TD-
8954 (Kenakin, 1997). Concentration ratios (CR) were calculated
Frontiers in Pharmacology | Gastrointestinal Pharmacology May 2011 | Volume 2 | Article 25 | 2
Beattie et al. Pharmacology of TD-8954
as the ratio of the EC50 values in the presence and absence of
antagonist. The log[CR-1] was plotted against the log[GR113808],
resulting in a linear relationship with the slope not signiﬁcantly
different from unity. The slope was therefore constrained to unity,
and the X-intercept was extrapolated to provide a measure of the
pKb value for GR113808.
5-HT4 receptor selectivity
Off-target selectivity screening was conducted at Theravance, Inc.
or at a contract research organization (CEREP, Paris, France).
Conventional radioligand binding studies were conducted using,
in the majority of assays, membranes prepared from cell lines
transfected with the respective human recombinant receptor, ion
channel, or transporter. The percent inhibition of speciﬁc binding
by TD-8954, at a single concentration (1μM, in duplicate), was
determined. Conventional whole cell voltage-clamp techniques
were used to examine the interaction of TD-8954 (3 μM) with
neuronal (rat Nav1.2) and cardiac (human Nav1.5) voltage-gated
sodium channels and hERG potassium channels (see Smith et al.,
2006, 2008).
Functional 5-HT4 receptor activity in the guinea pig colonic
longitudinal muscle/myenteric plexus
Adult, male Dunkin Hartley guinea pigs (200–350 g, Harlan,
Chicago, IL, USA) were euthanized by CO2 asphyxiation. The
distal colon was removed and placed in Krebs–Henseleit phys-
iological buffer containing (in mM): KCl (4.7), KH2PO4 (1.2),
MgSO4 anhydrous (1.2),NaCl (118.1),d-glucose (11.1),NaHCO3
(25.0),CaCl2 (2.6),ondansetron (0.003; to block 5-HT3 receptors),
methysergide (0.001; to antagonize 5-HT1 and 5-HT2 receptors),
and indomethacin (0.001; to inhibit prostaglandin synthesis).
The colon was cut into 5 cm lengths, and the longitudinal mus-
cle/myenteric plexus (LMMP) carefully peeled off. The LMMPwas
then mounted, under a tension of 10mN, in a 10-mL tissue bath
ﬁlled with Krebs–Henseleit buffer (37˚C, aerated continuously
with 95% O2/5% CO2).
Tissues were washed three times (at 0, 15, and 30min after
mounting) and then challenged (at 45min) with 5-HT at a con-
centration (0.3μM) previously established to evoke a maximal
contractile response. Once the contraction had reached its maxi-
mum, tissues were washed four times (2min between each wash),
and once more 10min later. An additional priming challenge of
5-HT (0.3μM) was made 15min later. Following further washing
prior to, and after a third 5-HT (0.3μM) challenge, a cumula-
tive concentration–response curve to 5-HT, tegaserod, mosapride,
cisapride, prucalopride, or TD-8954 was constructed. TD-8954
concentration–response curves were also constructed in tissues
previously exposed for 15min to the selective 5-HT4 receptor
antagonist, piboserod (0.3μM; Gaster et al., 1995) or vehicle.
Changes in colonic isometric force were recorded by means of a
force transducer (World Precision Instruments, model Fort 100),
ampliﬁer (Astro Med., model S48), and a data acquisition sys-
tem (Biopac MP100, Acknowledge™ Waveform Acquisition and
Analysis software). Contractile responses to test compounds were
normalized to those of the last, primed 5-HT (0.3μM) response
in each tissue. Data were analyzed by non-linear regression analy-
sis with GraphPad Prism using the four-parameter sigmoidal
concentration–effectmodel. The pEC50 and IA (i.e., themaximum
compound-evoked response expressed as a percentage of the fully
primed 5-HT maximum) were derived and reported for each test
agent.
GUINEA PIG COLONIC TRANSIT
Adult, male Dunkin Hartley guinea pigs (220–300 g, Harlan,
Chicago, IL, USA) were acclimated to their holding room (tem-
perature controlled at 21± 1˚C and 12:12 h light–dark cycle com-
mencing at 7 a.m.) for approximately 1week prior to surgery.
A standard guinea pig diet (7006, Harlan Teklad) and drinking
water were provided ad libitum. Guinea pigs were anesthetized
with isoﬂurane (2–3%, in oxygen) in an induction chamber.
Maintenance of anesthesia was achieved with isoﬂurane (2–3%)
administered via a nose cone. Themid-scapular area and abdomen
were shaved and cleansed with betadine and 70% isopropanol.
A small incision was made in the lower abdomen to expose
the proximal colon. After isolation, a small incision was made
in the proximal colon (approximately 2 cm from the cecum)
and a cannula consisting of micro-renathane (MRE-040) tubing
with a 2-cm silicone rubber tip (RenaSil™; 0.047′′ OD× 0.025′′
ID) was introduced and advanced approximately 2 cm toward
the aboral end. A purse-string suture (Ethicon, 6-0 silk) was
used to anchor the cannula in the colon and Baytril antibiotic
(2.27%) was then applied topically to the colonic surgical site.
The muscle layer was closed with a 4-0 Vicryl suture. The can-
nula was then secured to the nearby musculature with a 6-0
silk suture, tunneled under the skin and exteriorized at the mid-
scapular region. The cannula was ﬂushed and locked with ster-
ile saline (Baxter), sealed with a sterile stainless steel pin, and
secured to the back of the neck with a wound clip. The inci-
sions in the peritoneum and abdomen were cleansed of blood
and closed with a 3-0 Ethilon suture (Ethicon). Subcutaneous
(s.c.) warmed lactated-Ringer’s solution (3mL) was adminis-
tered immediately after surgery in addition to an intramuscular
injection of the opioid analgesic, Buprenex® (buprenorphine,
0.03mg/kg).
At least 5 days after surgery, guinea pigs were assigned ran-
domly to a study group. Animals were dosed with test agent or
vehicle (2mL/kg s.c.), and 5min later, each guinea pig was gen-
tly restrained and a non-absorbable marker (0.2mL) was infused
into the proximal colon via the implanted cannula. The marker
consistedof 6 g of carmine reddyeper 15mLof carboxymethyl cel-
lulose (0.5%). The study personnel were blinded to the treatment
that each animal received. Animal cages were visually inspected for
the presence of excreted red fecal pellets at 30-min intervals until
each guinea pig had excreted pellets containing the red marker, or
until 10 h had lapsed from the time of the marker injection. In the
case that an animal failed to produce red fecal pellets within 10 h,
the animal was left overnight in a clean cage and inspected the
following morning. If excretion of dye occurred overnight, a value
of 10 h was assigned. The whole colonic transit was deﬁned as
the time that lapsed between marker injection and the appear-
ance of dye in the feces. Data for each treatment group were
expressed as a mean percent increase (±SEM) in colonic transit
time relative to vehicle-treated animals. Differences between treat-
ment groups were determined using one-way analysis of variance
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(ANOVA) with a Dunnett’s post hoc test (p < 0.05 considered to
be statistically signiﬁcant).
RAT ESOPHAGEAL RELAXATION
The technique of digital sonomicrometry was used (Adelson and
Million, 2004; Armstrong et al., 2006). Adult, male Sprague-
Dawley rats (250–350 g, Harlan, Chicago, IL, USA) were accli-
mated to the colony room (temperature controlled at 21± 1˚C
and 12:12 h light–dark cycle commencing at 7 a.m.) for at least
5 days prior to investigation. Standard rat diet (Harlan Teklad) and
drinking water were available ad libitum. Rats were anesthetized
with isoﬂurane (2–3%) in an induction chamber and anesthe-
sia was then maintained with isoﬂurane (2–3%) via a nose cone
for the duration of each experiment. Animals were placed, in a
supine position, on a heated pad to maintain body temperature
at 37–38˚C [monitored rectally with a sensor (Physitemp BAT-
12)]. A midline incision was made in the skin and muscle layers
of the abdomen, and the stomach and esophagus were exposed. A
small incision was made in the upper duodenum approximately
1 cm from the pyloric sphincter, to permit intraduodenal (i.d.)
administration of test agents. A micro-renathane catheter (MRE-
40 with a 1 cm RenaSil rubber tip) was inserted approximately
1.5 cm into the duodenum via the incision and closed with 6-0 silk
purse-string suture. Two piezoelectric crystals (1mm diameter;
Sonometrics Corp.) were gently glued, in a longitudinal orien-
tation, to the distal esophagus (1 cm from the lower esophageal
sphincter) using Vetbond tissue adhesive. The inter-crystal dis-
tance was approximately 2mm. The wires connecting the crystals
to the measurement device (Sonometrics Corp. TRX series 8) were
exteriorized through the abdominal incision site, which was then
closed with 4-0 Ethilon suture.
Following surgery, baseline esophageal tone was allowed to
stabilize over approximately 30min, prior to drug administra-
tion. The settings for the Sonometrics system were ﬁxed within
the Sonoview software (Sonometrics Corp., version 3.2.1) as fol-
lows: sampling rate= 99.4Hz, transmit pulse= 375 ns, inhibit
delay= 1.2–1.5mm, velocity of sound through biological tis-
sue= 1.59mm/μs. Drug vehicle, followed by increasing doses of
test compounds (0.5mL/kg) were administered cumulatively via
the duodenal cannula. Each dose was administered only when the
esophageal response to the preceding dose had reached a max-
imum (typically 15–20min). Changes in inter-crystal distance
(in mm) from resting levels were averaged for each treatment
group. The data were ﬁtted to a sigmoidal dose–response rela-
tionship with variable slope, and an ED50 value (i.e., the dose
resulting in 50% of the maximum response) was calculated using
Prism graphics software 3.0 (GraphPad, Inc.).
DOG GASTROINTESTINAL CONTRACTILITY
Five adult, female beagle dogs (6.5–8.5 kg, Marshall BioResources,
North Rose, NY, USA), were maintained in a temperature con-
trolled holding room at 21–24˚C and 12:12 h light–dark cycle
commencing at 7 a.m. for at least 7 days prior to surgery.Dogswere
fed at 8 a.m. and 6 p.m. with commercial dog food,while water was
available ad libitum. Under pentobarbital anesthesia (30mg/kg
i.v. for induction, 1–2mg/kg i.v. for maintenance), a strain gauge
transducer (R. B. Products, Stillwater, MN, USA, calibrated with
weights of 10–200 g) was sutured on to the antrum of the stom-
ach (1 cm above the pylorus), duodenum, and jejunum (10–12 cm
distal to the ligament of Treitz). Strain gauges were positioned
to record circular muscle activity (Bass and Wiley, 1972). The
strain gauge wiring was anchored securely to abdominal muscle
with four stainless steel sutures. The abdominal incision was then
closed around the wiring assembly. All dogs were treated with a
fentanyl (25μg) patch, which was applied 1 day prior to surgery
and removed 3–4 days post-surgery. At least 2 weeks were allowed
to lapse after surgery, before testing.
Dogs were fasted for 18 h prior to each study. The animals were
positioned in slings, and the strain gauges were connected to a
Grass (model 7P) polygraph to allow recording of the GI motil-
ity patterns. In fasted beagles, three phases of activity are evident
in the antrum, duodenum and jejunum: quiescence followed by
a pre-burst and then a burst period. After recording data for a
full motility cycle, and conﬁrming commencement of a quies-
cent period, each dog was dosed orally with TD-8954 (0.01 and
0.03mg/kg), tegaserod (0.1 and 0.3mg/kg), or vehicle (1mL/kg
over 5 s), followed by a 10mL ﬂush of water. After dosing, GI
motility was monitored for 3 h. Dogs were allowed at least 4 days
between treatments, the sequence of which was based on a Latin
square design.
The area under the contractile force-time curve (AUC) of GI
muscle contractions was measured directly from the polygraph
tracings by means of a Numonics™ 2210 digitizing tablet in con-
junction with an IBM 80486 computer and Sigma Scan™ analysis
software (Jandel Scientiﬁc). Data were expressed as mean values
(±SEM) for each treatment group.
HUMAN SINGLE ASCENDING DOSE STUDY
A Phase 1, double-blind, randomized, placebo-controlled, single
ascending dose study was performed, consisting of seven sequen-
tial cohorts. In each cohort, eight healthy male and female subjects
(18–50 years old) were randomized such that six subjects received
a single oral dose of TD-8954 (0.1, 0.5, 1, 2, 5, 10, or 20mg) and
two subjects received placebo. The lowest dose of TD-8954 was
formulated as an aqueous solution, while the other doses were
administered as a powder in capsule. All subjects were conﬁned
to the clinical research unit from day 1 (admission) until after the
48-h post-dose safety assessments, and then returned on day 7
for a follow-up visit. A bowel diary was used to record the date
and time of each bowel movement after dosing. The bowel diary
was reviewed daily and before discharge. Blood samples were col-
lected to assess the pharmacokinetics of TD-8954, and safety and
tolerability were closely monitored.
MATERIALS
Standard biochemical and tissue culture reagents were purchased
from Sigma-Aldrich (St Louis, MO, USA) and Invitrogen (Carls-
bad, CA, USA) respectively. [3H]GR113808 was purchased from
Amersham Biosciences (Newark,NJ,USA). The Flashplate Adeny-
lyl Cyclase Activation Assay System was purchased from Perkin-
Elmer (Boston, MA, USA). TD-8954, prucalopride, mosapride,
and piboserod were synthesized at Theravance, Inc. GR113808,
tegaserod and cisapride were purchased from Tocris Cookson
(Ellisville,MO,USA),Apin Chemicals (Abingdon,Oxon,UK) and
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Sequoia Research Products (Pangbourne, UK), respectively. Car-
bachol, 5-HT, and ketanserinwere purchased fromSigma-Aldrich.
For in vitro radioligand binding and cAMP accumulation studies,
stock agonist solutions (10mM) were prepared in DMSO, diluted
to 400μM with 50mM HEPES (pH 7.4) at 25˚C, containing 0.1%
BSA, and serial dilutions prepared in the same buffer. For isolated
tissue studies, 10mM solutions, prepared in DMSO, were diluted
serially in sterile water. For in vivo studies, TD-8954 and prucalo-
pride were dissolved in 5% dextrose in distilled water (D5W)
or 0.9% saline, while tegaserod and mosapride were prepared in
10% sulfobutyl ether-beta cyclodextrin (10% SBE/CD), and cis-
apride was dissolved in 10% SBE/CD containing citrate (20mM).
Doses were expressed with respect to the free base weights of each
compound.
RESULTS
5-HT4 RECEPTOR BINDING AND cAMP ACCUMULATION
TD-8954, tegaserod, prucalopride, cisapride, and mosapride pro-
duced a concentration-dependent inhibition of [3H]-GR113808
binding to HEK293-h5-HT4(c) cell membranes. Comparison of
the mean pKi values for the compounds (Table 1) indicated
a rank order of afﬁnity of TD-8954 (pKi = 9.4)> tegaserod
(pKi = 8.6)> prucalopride (pKi = 7.6)> cisapride (pKi = 7.1)>
mosapride (pKi = 6.8). In cAMP accumulation assays, using
HEK-293 cells stably transfected with the h5-HT4(c) recep-
tor, TD-8954, tegaserod, cisapride, prucalopride, and mosapride
produced a concentration-dependent increase in cAMP. The
rank order of potency was TD-8954 (pEC50 = 9.3)> tegaserod
(pEC50 = 8.7)> prucalopride (pEC50 = 7.9)> cisapride (pEC50 =
7.4)>mosapride (pEC50 = 6.3). The mean IAs of TD-8954,
tegaserod, cisapride, prucalopride, and mosapride, relative to 5-
HT (100%) were 83, 120, 101, 109, and 22%, respectively; Table 1).
In antagonist inhibition studies, increasing concentrations of
GR113808 produced rightward shifts in the 5-HT and TD-8954
concentration–response curves, resulting in pKb values (with 95%
conﬁdence intervals) of 10.3 (95% CI: 10.2–10.4) and 10.3 (95%
CI: 10.2–10.5), respectively.
5-HT4 RECEPTOR SELECTIVITY
TD-8954 was >2,000-fold selective for h5-HT4(c) receptors over
other 5-HT receptors (Table 2), and all non-5-HT receptors,
transporters, ion channels, and enzymes tested (Table 3). TD-
8954 (3μM) had no effect on hERG potassium currents (n = 6
cells) while cisapride (20 nM) was associated with a mean inhibi-
tion of 65% in the same cells. Exposure to TD-8954 (3μM) for
3min had no effect on the magnitude of the inward rat Nav1.2a
or human Nav1.5 sodium currents (n = 3 cells for each).
GUINEA PIG COLONIC LONGITUDINAL MUSCLE/MYENTERIC PLEXUS
TD-8954, tegaserod, cisapride, prucalopride, and mosapride
produced concentration-dependent contraction of the guinea
pig colonic LMMP (Figure 2). Comparison of the mean
pEC50 (±SEM) values for the compounds indicated a
rank order of potency of TD-8954 (pEC50 = 8.6)> tegaserod
(pEC50 = 7.9)= prucalopride (pEC50 = 7.7)> cisapride (pEC50 =
7.0)>mosapride (pEC50 = 5.4). TD-8954 had a mean IA (55% of
the 5-HTmaximum) lower than that of cisapride andprucalopride
(75 and81%,respectively),but higher than that of tegaserod (45%)
and mosapride (37%; Table 1). Incubation of tissues with the
selective 5-HT4 receptor antagonist, piboserod (0.3μM), resulted
in a 614-fold shift (apparent pKb value= 9.3) of the TD-8954
concentration–response curve (data not shown).
Table 2 | Binding affinity (pKi) ofTD-8954 at 5-HT receptor subtypes.
Receptor Radioligand [Radioligand] (nM) pKi
Human 5-HT1A [3H]-8-OH-DPAT 0.5 <6
Rat 5-HT1B [125I]-CYP 0.1 <6
Bovine 5-HT1D [3H]-serotonin 2 <6
Human 5-HT2A [3H]-ketanserin 0.5 <6
Human 5-HT2B [3H]-LSD 1.2 <6
Human 5-HT2C [3H]-mesulergine 1 <6
Human 5-HT3a [3H]-GR65630 0.5 <4
Human 5-HT4(c) [3H]-GR113808 0.15 9.4
Human 5-HT5a [3H]-LSD 1 <6
Human 5-HT6 [3H]-LSD 2 <6
Human 5-HT7 [3H]-LSD 4 <6
Inhibition of radioligand binding to non-5-HT4 receptor subtypes was determined
in duplicate at a single test concentration (1μM, with the exception of the 5-HT3a
receptor subtype, at which concentrations up to 100μM were evaluated).
Table 1 | Human 5-HT4(c) binding affinity (HEK293-h5-HT4(c); pKi), and human (HEK293-h5-HT4(c)) and guinea pig colonic longitudinal
muscle/myenteric plexus (LMMP) agonist potency (pEC50) and intrinsic activity (IA; % 5-HT maximum) values forTD-8954, cisapride,
mosapride, prucalopride, and tegaserod.
Human 5-HT4(c)
receptor affinity
Human 5-HT4(c)
agonist activity
Guinea pig colonic LMMP
contractile activity
pKi
(mean±SEM)
n pEC50
(mean±SEM)
IA (mean % 5-HT
max±SEM)
n pEC50
(mean±SEM)
IA (mean % 5-HT
max±SEM)
n
TD-8954 9.4±0.04 6 9.3±0.11 83±6 6 8.6±0.1 55±2 24
Cisapride 7.1±0.05 11 7.4±0.11 101±4 11 7.0±0.1 75±3 10
Mosapride 6.8±0.09 6 6.3±0.11 22±3 6 5.4±0.1 37±2 3
Prucalopride 7.6±0.03 11 7.9±0.11 109±5 11 7.7±0.1 81±2 24
Tegaserod 8.6±0.03 11 8.7±0.07 120±5 11 7.9±0.3 45±3 13
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Table 3 | Binding data (% inhibition of specific binding and pKi values) ofTD-8954 at non-5-HT receptors, transporters, ion channels, and
enzymes.
Receptor Radioligand [Radioligand] (nM) % Inhibition of specific
binding (1μM)
pKi
BIOGENIC AMINE RECEPTORS
Human A1 [3H]-DPCPX 1 −4 <6
Human A2A [3H]-CGS 21680 6 16 <6
Rat α1 (non-selective) [3H]-prazosin 0.25 −1 <6
Rat α2 (non-selective) [3H]-RX 821002 0.5 7 <6
Human D1 [3H]-SCH 23390 0.3 −2 <6
Human D2S [3H]-spiperone 0.3 6 <6
Human D4.4 [3H]-spiperone 0.3 6 <6
Human D5 [3H]-SCH 23390 0.3 −12 <6
Guinea pig H1 [3H]-pyrilamine 1 −7 <6
Guinea pig H2 [125I]-APT 0.1 4 <6
Human M1 [3H]-NMS 1 – <6
Human M2 [3H]-NMS 1 – 6.1
Human M3 [3H]-NMS 1 – <5
Human M4 [3H]-NMS 1 – 5.5
Human M5 [3H]-NMS 1 – <5
Human β1 [3H]-DHA 0.8 −8 <6
Human β2 [3H]-DHA 0.8 −17 <6
PEPTIDE RECEPTORS
Human AT1 [125I]-[Sar1, Ile8]-ATII 0.05 2 <6
Rat BB (non-selective) [125I]-[Tyr4]-bombesin 0.01 4 <6
Human B2 [3H]-bradykinin 0.2 3 <6
Human CGRP [125I]-hCGRPα 0.03 −18 <6
Human CCK1 (CCKA) [125I]-CCK-8 0.08 −8 <6
Human CCK2 (CCKB) [125I]-CCK-8 0.06 −1 <6
Rat CRF1 [125I]-Tyr0-CRF 0.1 −6 <6
Human ETA [125I]-endothelin-1 0.03 0 <6
Human ETB [125I]-endothelin-1 0.03 5 <6
Rat galanin (non-selective) [125I]-galanin 0.05 1 <6
Human motilin [125I]-motilin 0.05 14 <6
Human NK1 [125I]-[Sar9, Met(O2)11]-SP 0.15 −2 <6
Human NK2 [125I]-NKA 0.1 −8 <6
Human NK3 [3H]-SR 142801 0.4 −3 <6
HumanY1 [125I]-peptideYY 0.025 −11 <6
HumanY2 [125I]-peptideYY 0.015 −5 <6
Rat NT (non-selective) [125I]-Tyr3-neurotensin 0.05 4 <6
Rat PACAP (PAC1) [125I]-PACAP1–27 0.02 −3 <6
Mouse sst (non-selective) [125I]-Tyr11-somatostatin 0.05 −6 <6
Human VPAC1 (VIP1) [125I]-VIP 0.04 2 <6
Human VPAC2 (VIP2) [125I]-VIP 0.05 −19 <6
Human V1a [3H]-AVP 0.3 1 <6
Human V2 [3H]-AVP 0.3 −11 <6
OPIATE RECEPTORS
Human δ2 [3H]-DADLE 0.5 0 <6
Guinea pig κ kappa [3H]-U69593 0.7 22 <6
Human μ [3H]-DAMGO 0.5 −30 <6
TRANSPORTERS
Human norepinephrine [3H]-nisoxetine 1 6 <6
Rat dopamine [3H]-GBR12935 0.8 3 <6
Human 5-HT [3H]-imipramine 2 0 <6
(Continued )
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Table 3 | Continued
Receptor Radioligand [Radioligand] (nM) % Inhibition of specific
binding (1μM)
pKi
ION CHANNELS
Rat AMPA [3H]-AMPA 8 −4 <6
Rat kainate [3H]-kainic acid 5 −6 <6
Rat NMDA [3H]-CGP 39653 5 −6 <6
Rat α4β2 nAChR (α-BGTX-insensitive) [3H]-cytisine 1.5 −2 <6
Rat α7 nAChR (α-BGTX-sensitive) [125I]-α-bungarotoxin 1 3 <6
Rat Ca2+ channel (L, DHP site) [3H]-(+)PN 200-110 0.04 7 <6
Rat Ca2+ channel (L, diltiazem site) [3H]-diltiazem 5 13 <6
Rat Ca2+ channel (L, verapamil site) [3H]-(−)D 888 0.5 21 <6
Rat Ca2+ channel (N) [125I]-ω-conotoxin 0.001 −11 <6
K+ATP channel [3H]-glibenclamide 0.1 5 <6
K+V channel [125I]-α-dendrotoxin 0.01 −5 <6
SK+Ca channel [125I]-apamin 0.004 −4 <6
OTHER
Human CB1 [3H]-WIN 55212-2 2 8 <6
Rat GABA (non-selective) [3H]-GABA 10 −6 <6
Rat P2Y [35S]-dATP αS 10 8 <6
Rat σ (non-selective) [3H]-DTG 8 30 <6
Enzyme Substrate/stimulus/ [Substrate/stimulus/ % Inhibition of pIC50
tracer tracer] (μM) control (1μM)
Human COX1 Arachidonic acid 0.3 2 <6
Human COX2 Arachidonic acid 50 −36 <6
Human PDE4 [3H]-cAMP+ cAMP 1 −19 <6
Rat adenylyl cyclase ATP 500 5 <6
Human acetylcholinesterase AMTCh 50 2 <6
FIGURE 2 | Concentration–response curves toTD-8954 (n =24),
tegaserod (n =13), cisapride (n =10), mosapride (n =3), prucalopride
(n =24), and 5-HT (n =26) in the guinea pig isolated colonic
LMMP preparation. Values are expressed as the mean (±SEM) change in
tension, as a percentage of the primed 5-HT (0.3μM) response in the same
tissue.
GUINEA PIG COLONIC TRANSIT
In vehicle (2mL/kg s.c.)-treated guinea pigs, the mean time taken
for excretion of the ﬁrst fecal pellet containing red dye was
typically between 220 and 310min. Following s.c. dosing, TD-
8954, tegaserod, cisapride, mosapride (each at 0.03–3mg/kg) and
prucalopride (0.03–10mg/kg) increased colonic transit, reducing
the time taken for excretion of the dye, compared to vehicle-treated
animals (Figure 3), although statistical signiﬁcance (p < 0.05,one-
way ANOVA with a Dunnett’s post hoc test) was achieved only for
all of the TD-8954 doses and for the 0.3 and 3mg/kg prucalopride
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FIGURE 3 |The effects ofTD-8954, tegaserod, cisapride, mosapride (each at 0.03–3mg/kg), prucalopride (0.03–10mg/kg), and vehicle (2mL/kg),
administered s.c., on the colonic transit of dye in conscious guinea pigs (n =9–22 for each group; *p <0.05; ANOVA followed by Dunnett’s post hoc
test vs. vehicle).
doses. TD-8954wasmore potent than tegaserod,prucalopride, cis-
apride, and mosapride, being signiﬁcantly active at the lowest dose
tested (0.03mg/kg). At 0.03mg/kg, TD-8954 had already achieved
its maximum effect.
RAT ESOPHAGEAL RELAXATION
Following crystal placement on the rat esophagus, 30min proved
sufﬁcient to establish a stable sonomicrometry recording. No
spontaneous changes in esophageal muscle length were observed
after this stabilization period. Following cumulative i.d. dosing,
TD-8954, prucalopride, tegaserod (each 0.03–10mg/kg), cisapride
(0.3–10mg/kg), and mosapride (0.3–10mg/kg), but not their
vehicles (1–10mL/kg) evoked a dose-dependent increase in inter-
crystal distance, consistent with esophageal relaxation (Figure 4).
The ED50 values (with 95% conﬁdence limits) for TD-8954 and
prucalopride were 0.15 (0.08–0.26) and 0.18 (0.13–0.25) mg/kg,
respectively. Accurate ED50 values could not be calculated for
tegaserod, cisapride, and mosapride as solubility limitations pre-
cluded veriﬁcation that their maximum relaxations had been
achieved. To compare the potencies of each compound, the doses
of TD-8954, prucalopride, tegaserod, cisapride, and mosapride
associated with a relaxation response of 0.1mm were calculated
(i.e., 0.23, 0.30, 2.43, 2.66, and 4.37mg/kg, respectively; Figure 4).
TD-8954was therefore equieffective, on a dose basis,with prucalo-
pride following i.d. dosing, and 11-, 12-, and 19-fold more potent
than tegaserod, cisapride, and mosapride, respectively.
DOG GASTROINTESTINAL CONTRACTILITY
The quiescent phase of the antrum, duodenum, and jejunum
motility cycle generally lasted for 50–60min before transition-
ing into the pre-burst period (muscle contractions of gradually
increasing magnitude occurring at random, with a duration of
30–60min), followed by the burst period (vigorous and frequent
contractions,with a duration of 5–15min). Following oral admin-
istration of vehicle (1mL/kg), there was little or no change in
the activity of the antrum, duodenum, or jejunum; the expected
motility patterns characteristic of fasted beagles were maintained
throughout the observation period (Figures 5 and 6). TD-8954
(0.01 and 0.03mg/kg) and tegaserod (0.1 and 0.3mg/kg) pro-
duced increases in contractility in the antrum, duodenum, and
jejunum (Figure 5). The onset of contractile activity with TD-
8954 occurred typically within 10min of dosing (Figure 6).
Comparison of the activities of TD-8954 and tegaserod indi-
cated that TD-8954 was statistically signiﬁcantly more potent than
tegaserod in the antrum, duodenum, and jejunum following oral
administration (p < 0.05, ANOVA, followed by Dunnett’s post hoc
test).
FIGURE 4 | Dose-dependent relaxation [mean (±SEM) change in
inter-crystal distance (in mm)] of the rat esophagus following i.d.
administration ofTD-8954 (0.03–10mg/kg; n =4), prucalopride
(0.03–10mg/kg; n =4), tegaserod (0.03–10mg/kg; n =6), cisapride
(0.3–10mg/kg; n =4), and mosapride (0.3–10mg/kg; n =4).
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FIGURE 5 | Contractile activity following oral dosing ofTD-8954 (0.01 and
0.03mg/kg; n =5; left-hand columns), tegaserod (0.1 and 0.3mg/kg;
n =6; right-hand columns), and vehicles (n =5 or 6) in the canine
antrum, duodenum, and jejunum. Data are expressed as the mean (±SEM)
cumulative contractile AUC in 10-min periods for 3 h post-dosing (at 0min).
Data are analyzed using a two-way analysis of variance with a Bonferroni
post hoc test (*,#p <0.05 for the 0.01, 0.03, and 0.3mg/kg treatment groups,
respectively, vs. vehicle.
HUMAN SINGLE ASCENDING DOSE STUDY
In healthy human subjects, GI prokinetic effects of TD-8954
(0.1–20mg) were observed (Figure 7). The number of bowel
movements from 0 to 24 h after each TD-8954 dose was
increased signiﬁcantly relative to placebo (p < 0.03 upon com-
parison of each TD-8954 treated group and placebo, based
on Wilcoxon rank sum test). Compared to placebo, each TD-
8954 dose was associated with a statistically signiﬁcant reduction
in the time to ﬁrst bowel movement (p < 0.05 for all treat-
ment groups comparing difference in survival function between
each TD-8954 treated group and placebo obtained by log-rank
test).
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FIGURE 6 | Representative traces demonstrating the effects of oral
dosing ofTD-8954 (0.01mg/kg) and vehicle on the contractility of the
antrum, duodenum, and jejunum of conscious, fasted dogs.
FIGURE 7 | (A)The mean number of bowel movements, and (B) the
cumulative percentage of subjects responding with a bowel movement
within 24 h following the oral dosing of TD-8954 (0.1–20mg) and placebo to
healthy human subjects (n=5–14 per group). Each dose of TD-8954
produced a statistically signiﬁcant effect compared to placebo (*p <0.03,
Wilcoxon rank sum test vs. placebo).
DISCUSSION
Disorders of reducedGImotility, such as IBS-C, chronic idiopathic
constipation, gastroparesis, post-operative ileus, and functional
dyspepsia have a signiﬁcant impact on the quality of life of affected
individuals. Prior to their removal from the market, cisapride and
tegaserod provided some relief to patients afﬂicted with these dis-
orders (Prather et al., 2000; Evans et al., 2004; Ford et al., 2009).
Limitations in their efﬁcacy have been attributed to a lack of selec-
tivity for the 5-HT4 receptor subtype (Beattie and Smith, 2008;
De Maeyer et al., 2008). Cisapride is a potent 5-HT2A and 5-HT2B
receptor antagonist,while tegaserodhas afﬁnity for,and/or antago-
nist potency at, 5-HT1B, 5-HT2A, and 5-HT2B receptors (Buchheit
et al., 1995; Beattie et al., 2004; De Maeyer et al., 2008). Interac-
tions of cisapride or tegaserod with non-5-HT receptors have also
been proposed to underlie cardiac arrhythmic or ischemic adverse
events. It is now well established that cisapride can induce ventric-
ular tachycardia, ventricular ﬁbrillation, and torsades de pointes
as a result of potent cardiac hERG potassium channel inhibitory
activity, particularly when cytochrome P450 3A4 substrates are
co-administered (Mohammad et al., 1997). The perceived risk of
cardiovascular ischemic events with tegaserod, initially identiﬁed
upon reviewing clinical trial data, has been questioned recently
(Anderson et al., 2009; Loughlin et al., 2010). It is clear, however,
that a signiﬁcant unmet medical need remains for new therapeutic
agents that will be efﬁcacious and well tolerated in patients with
functional GI disorders. One approach has been the development
of selective 5-HT4 receptor agonists, such as velusetrag (Beattie
et al., 2008a; Smith et al., 2008; Goldberg et al., 2010), prucalo-
pride (Briejer et al., 2001a; Camilleri et al., 2008), and TD-8954
(Beattie et al., 2008b),which, it is believed,will provide robust efﬁ-
cacy with acceptable tolerability and safety for patients. TD-8954,
the subject of this study, is one of the most potent and selective
5-HT4 receptor agonists described to date.
The in vitro data demonstrated that TD-8954 had high afﬁn-
ity and potency at the human 5-HT4 receptor (pKi and pEC50
values of 9.4 and 9.3, respectively). In each assay, TD-8954 was
signiﬁcantly more potent than each of the comparator 5-HT4 ago-
nists tested in parallel, an observation consistent with that made
previously in experiments with human isolated colonic circular
muscle preparations (Beattie et al., 2008b). Activation of the 5-
HT4 receptor by TD-8954 was conﬁrmed in vitro by antagonist
inhibition,where the GR113808 pKb value was consistent with the
[3H]-GR113808 binding pKd and antagonist pKb values reported
previously against 5-HT and tegaserod (Smith et al., 2008), pro-
viding further evidence of a 5-HT4 receptor-mediated elevation
of cAMP. TD-8954 had moderate IA at human recombinant 5-
HT4 receptors and endogenous 5-HT4 receptors in the guinea pig
colonic LMMP. Optimal target activation to induce a physiologi-
cal response is dependent upon, amongst other things, the IA of
an agonist and the receptor reserve in the target tissue (Grim-
wood and Hartig, 2009). While TD-8954 had moderate 5-HT4
receptor agonist IA in vitro, robust in vivo GI prokinetic or 5-
HT4 agonist activity, to at least the same degree as standards with
higher IA in vitro, was noted in guinea pigs, rats, and dogs. The
data suggest that a particularly low level of agonist activity in
the in vitro assays (e.g., such as that evident with mosapride) is
required before reduced efﬁcacy is observed in vivo, consistent
with a large 5-HT4 receptor reserve. TD-8954 had >2,000-fold
selectivity for the human 5-HT4(c) receptor over all other targets
tested. Notably, TD-8954, unlike tegaserod or cisapride, had no
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afﬁnity for 5-HT1B, 5-HT2A, 5-HT2B, or 5-HT3 receptors. Also,
in contrast to cisapride, TD-8954 had no inhibitory effect at the
hERG potassium channel.
The high 5-HT4 receptor agonist potency of TD-8954 was also
evident in vivo. TD-8954 (0.03–3mg/kg s.c.) produced a statis-
tically signiﬁcant increase in colonic transit in conscious guinea
pigs. Following TD-8954 administration and injection of carmine
red dye into the proximal colon, the time for excretion of the
ﬁrst fecal pellet containing the marker was markedly reduced. The
potent prokinetic activity of TD-8954 in this guinea pigmodel is in
keeping with the proposed role of 5-HT and 5-HT4 receptor acti-
vation in promoting GI motility (Muller-Lissner, 1987; Jin et al.,
1999; Briejer et al., 2001b; Ji et al., 2003). The TD-8954-induced
relaxation of the rat esophagus in this study is also consistent with
agonist activity at the 5-HT4 receptor (Triggle et al., 1988; Reeves
et al., 1991). The technique of digital sonomicrometry provides
a sensitive method to demonstrate the 5-HT4 receptor agonist-
mediated changes in rat esophageal tone (Armstrong et al., 2006).
In conscious, fasted dogs, TD-8954 (10 and 30μg/kg) produced
a dose-dependent increase in contractility of the antrum, duo-
denum, and jejunum following oral administration. TD-8954 was
clearlymore potent than tegaserod throughout the canineGI tract,
consistent with its superior 5-HT4 agonist potency in vitro and
oral pharmacokinetic properties (Theravance, Inc., data on ﬁle) in
this species. Considering the published data from similar models
(Gullikson et al., 1993; Briejer et al., 2001b; Tazawa et al., 2002),
the ﬁndings of this study are entirely consistent with activation of
5-HT4 receptors by TD-8954 in the canine GI tract.
Based on the positive preclinical pharmacodynamic effects of
TD-8954, a single ascending dose study was performed in healthy
human subjects. The data demonstrated that TD-8954 was asso-
ciated with an increase in bowel movement frequency and a
reduction in the time to ﬁrst stool compared to placebo. The high
potency noted in the preclinical assays was also noted clinically;
a dose as low as 0.1mg was associated with a prokinetic effect,
and 0.5mg produced a maximal response. The free plasma Cmax
and AUC0–24 values for TD-8954 following a single dose of 0.5mg
to humans are 3.4 and 36.2 nM/h, respectively. Assuming that the
free concentration of TD-8954 in plasma is equivalent to that at its
site of action in the GI tract, mean and maximal 5-HT4 receptor
occupancies in the 24-h period following a 0.5mg dose should be
approximately 80 and 90%, respectively. This apparent require-
ment for a high level of receptor occupancy to achieve a maximal
agonist response (Grimwood and Hartig, 2009) is consistent with
the moderate IA of TD-8954 demonstrated preclinically in the
in vitro assays.
CONCLUSION
TD-8954 is a potent and selective 5-HT4 receptor agonist in vitro
with robust in vivo GI activity in guinea pigs, rats, dogs, and
notably humans. As a result of its demonstrated prokinetic activ-
ity in healthy human subjects, TD-8954 may have value in the
treatment of patients with disorders of reduced GI motility.
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